|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DNAH14 |
Gene summary for DNAH14 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DNAH14 | Gene ID | 127602 |
| Gene name | dynein axonemal heavy chain 14 | |
| Gene Alias | C1orf67 | |
| Cytomap | 1q42.12 | |
| Gene Type | protein-coding | GO ID | GO:0001539 | UniProtAcc | Q0VDD8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 127602 | DNAH14 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 1.71e-02 | -1.44e-01 | -0.1869 |
| 127602 | DNAH14 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 5.12e-06 | -7.90e-02 | -0.1875 |
| 127602 | DNAH14 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 2.04e-04 | -4.87e-02 | -0.1883 |
| 127602 | DNAH14 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 5.49e-06 | 4.59e-02 | -0.1934 |
| 127602 | DNAH14 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 6.19e-11 | -8.04e-02 | -0.1917 |
| 127602 | DNAH14 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 1.00e-04 | -7.08e-02 | -0.1916 |
| 127602 | DNAH14 | NAFLD1 | Human | Liver | NAFLD | 8.51e-03 | 5.23e-01 | -0.04 |
| 127602 | DNAH14 | S43 | Human | Liver | Cirrhotic | 1.55e-04 | -1.64e-01 | -0.0187 |
| 127602 | DNAH14 | HCC1_Meng | Human | Liver | HCC | 3.68e-63 | -1.49e-02 | 0.0246 |
| 127602 | DNAH14 | HCC2_Meng | Human | Liver | HCC | 1.65e-11 | -9.36e-02 | 0.0107 |
| 127602 | DNAH14 | HCC1 | Human | Liver | HCC | 8.06e-05 | 2.96e+00 | 0.5336 |
| 127602 | DNAH14 | HCC2 | Human | Liver | HCC | 1.09e-09 | 3.43e+00 | 0.5341 |
| 127602 | DNAH14 | Pt13.a | Human | Liver | HCC | 1.13e-02 | -1.67e-01 | 0.021 |
| 127602 | DNAH14 | RNA-P10T2-P10T2-1 | Human | Lung | AAH | 1.30e-05 | 7.45e-01 | -0.1271 |
| 127602 | DNAH14 | RNA-P10T2-P10T2-3 | Human | Lung | AAH | 1.22e-02 | 4.93e-01 | -0.1408 |
| 127602 | DNAH14 | RNA-P10T2-P10T2-4 | Human | Lung | AAH | 5.54e-03 | 5.36e-01 | -0.138 |
| 127602 | DNAH14 | RNA-P17T-P17T-2 | Human | Lung | IAC | 6.99e-15 | 1.15e+00 | 0.3371 |
| 127602 | DNAH14 | RNA-P17T-P17T-4 | Human | Lung | IAC | 1.73e-15 | 1.26e+00 | 0.343 |
| 127602 | DNAH14 | RNA-P17T-P17T-6 | Human | Lung | IAC | 1.46e-13 | 1.12e+00 | 0.3385 |
| 127602 | DNAH14 | RNA-P17T-P17T-8 | Human | Lung | IAC | 3.39e-12 | 9.96e-01 | 0.3329 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05016 | Colorectum | AD | Huntington disease | 147/2092 | 306/8465 | 1.93e-19 | 9.26e-18 | 5.91e-18 | 147 |
| hsa05014 | Colorectum | AD | Amyotrophic lateral sclerosis | 164/2092 | 364/8465 | 4.28e-18 | 1.27e-16 | 8.09e-17 | 164 |
| hsa05022 | Colorectum | AD | Pathways of neurodegeneration - multiple diseases | 201/2092 | 476/8465 | 4.54e-18 | 1.27e-16 | 8.09e-17 | 201 |
| hsa050161 | Colorectum | AD | Huntington disease | 147/2092 | 306/8465 | 1.93e-19 | 9.26e-18 | 5.91e-18 | 147 |
| hsa050141 | Colorectum | AD | Amyotrophic lateral sclerosis | 164/2092 | 364/8465 | 4.28e-18 | 1.27e-16 | 8.09e-17 | 164 |
| hsa050221 | Colorectum | AD | Pathways of neurodegeneration - multiple diseases | 201/2092 | 476/8465 | 4.54e-18 | 1.27e-16 | 8.09e-17 | 201 |
| hsa050162 | Colorectum | SER | Huntington disease | 127/1580 | 306/8465 | 3.29e-21 | 1.37e-19 | 9.92e-20 | 127 |
| hsa050222 | Colorectum | SER | Pathways of neurodegeneration - multiple diseases | 168/1580 | 476/8465 | 6.23e-19 | 2.07e-17 | 1.50e-17 | 168 |
| hsa050142 | Colorectum | SER | Amyotrophic lateral sclerosis | 138/1580 | 364/8465 | 9.89e-19 | 2.99e-17 | 2.17e-17 | 138 |
| hsa050163 | Colorectum | SER | Huntington disease | 127/1580 | 306/8465 | 3.29e-21 | 1.37e-19 | 9.92e-20 | 127 |
| hsa050223 | Colorectum | SER | Pathways of neurodegeneration - multiple diseases | 168/1580 | 476/8465 | 6.23e-19 | 2.07e-17 | 1.50e-17 | 168 |
| hsa050143 | Colorectum | SER | Amyotrophic lateral sclerosis | 138/1580 | 364/8465 | 9.89e-19 | 2.99e-17 | 2.17e-17 | 138 |
| hsa050228 | Colorectum | FAP | Pathways of neurodegeneration - multiple diseases | 117/1404 | 476/8465 | 2.81e-06 | 4.47e-05 | 2.72e-05 | 117 |
| hsa050148 | Colorectum | FAP | Amyotrophic lateral sclerosis | 91/1404 | 364/8465 | 1.84e-05 | 2.36e-04 | 1.44e-04 | 91 |
| hsa050168 | Colorectum | FAP | Huntington disease | 73/1404 | 306/8465 | 5.54e-04 | 3.93e-03 | 2.39e-03 | 73 |
| hsa050229 | Colorectum | FAP | Pathways of neurodegeneration - multiple diseases | 117/1404 | 476/8465 | 2.81e-06 | 4.47e-05 | 2.72e-05 | 117 |
| hsa050149 | Colorectum | FAP | Amyotrophic lateral sclerosis | 91/1404 | 364/8465 | 1.84e-05 | 2.36e-04 | 1.44e-04 | 91 |
| hsa050169 | Colorectum | FAP | Huntington disease | 73/1404 | 306/8465 | 5.54e-04 | 3.93e-03 | 2.39e-03 | 73 |
| hsa0501620 | Endometrium | AEH | Huntington disease | 118/1197 | 306/8465 | 3.00e-27 | 2.44e-25 | 1.78e-25 | 118 |
| hsa0501420 | Endometrium | AEH | Amyotrophic lateral sclerosis | 123/1197 | 364/8465 | 2.17e-22 | 7.82e-21 | 5.72e-21 | 123 |
| Page: 1 2 3 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DNAH14 | SNV | Missense_Mutation | novel | c.1578N>C | p.Glu526Asp | p.E526D | Q0VDD8 | protein_coding | tolerated(0.12) | benign(0.423) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| DNAH14 | SNV | Missense_Mutation | novel | c.6913N>A | p.Glu2305Lys | p.E2305K | Q0VDD8 | protein_coding | tolerated(0.08) | possibly_damaging(0.501) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| DNAH14 | SNV | Missense_Mutation | c.862G>A | p.Asp288Asn | p.D288N | Q0VDD8 | protein_coding | deleterious(0.04) | benign(0.336) | TCGA-A2-A0CL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
| DNAH14 | SNV | Missense_Mutation | rs199634734 | c.82N>G | p.Val28Gly | p.V28G | protein_coding | tolerated(0.62) | possibly_damaging(0.847) | TCGA-A2-A1G0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD | |
| DNAH14 | SNV | Missense_Mutation | novel | c.8569A>G | p.Thr2857Ala | p.T2857A | Q0VDD8 | protein_coding | tolerated(0.45) | benign(0.067) | TCGA-A2-A4S1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DNAH14 | SNV | Missense_Mutation | novel | c.1273G>T | p.Leu425Phe | p.L425F | protein_coding | tolerated(0.1) | possibly_damaging(0.725) | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | |
| DNAH14 | SNV | Missense_Mutation | c.2398N>C | p.Glu800Gln | p.E800Q | Q0VDD8 | protein_coding | tolerated(0.71) | benign(0.015) | TCGA-A7-A26H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD | |
| DNAH14 | SNV | Missense_Mutation | rs199634734 | c.82T>G | p.Val28Gly | p.V28G | protein_coding | tolerated(0.62) | possibly_damaging(0.847) | TCGA-AC-A23C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | chemo | CR | |
| DNAH14 | SNV | Missense_Mutation | rs41268715 | c.9694N>C | p.Glu3232Gln | p.E3232Q | Q0VDD8 | protein_coding | tolerated(0.21) | possibly_damaging(0.571) | TCGA-AC-A2QJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD |
| DNAH14 | SNV | Missense_Mutation | novel | c.4909N>A | p.Glu1637Lys | p.E1637K | Q0VDD8 | protein_coding | deleterious(0.04) | benign(0.36) | TCGA-AC-A6IW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |